Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more) Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neogenomics Inc NEO

Healthcare
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment... see more

Recent & Breaking News (NDAQ:NEO)

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

Accesswire 2 days ago

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference

Accesswire November 14, 2023

NeoGenomics Reports Third Quarter 2023 Results

Accesswire November 6, 2023

NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios

Accesswire October 24, 2023

NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023

Accesswire October 17, 2023

NeoGenomics Reports Second Quarter 2023 Results

Accesswire August 8, 2023

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

Accesswire July 27, 2023

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

Accesswire July 18, 2023

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

Accesswire June 29, 2023

NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

Accesswire June 15, 2023

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

Accesswire June 5, 2023

NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference

Accesswire June 1, 2023

NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO

Accesswire May 30, 2023

NeoGenomics Reports First Quarter 2023 Results

Accesswire May 8, 2023

NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference

Accesswire May 3, 2023

NeoGenomics to Announce First Quarter 2023 Financial Results

Accesswire April 17, 2023

NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Accesswire April 11, 2023

NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023

Accesswire April 6, 2023

NeoGenomics to Host Investor Day on April 4, 2023

Accesswire March 27, 2023

Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care

Business Wire March 22, 2023